Surgical resection for recurrent retroperitoneal leiomyosarcoma and liposarcoma

被引:18
|
作者
Nathenson, Michael J. [1 ]
Barysauskas, Constance M. [2 ]
Nathenson, Robert A. [3 ]
Regine, William F. [4 ]
Hanna, Nader [4 ]
Sausville, Edward [4 ]
机构
[1] Dana Farber Canc Inst, Ctr Sarcoma & Bone Oncol, 450 Brookline Ave, Boston, MA 02215 USA
[2] Dana Farber Canc Inst, Dept Biostat & Computat Biol, 450 Brookline Ave, Boston, MA 02215 USA
[3] Univ Penn, 3440 Market St Philadelphia, Philadelphia, PA 19146 USA
[4] Univ Maryland, Greenebaum Canc Ctr, South Greene St Suite 9d10 Baltimore, Baltimore, MD 21201 USA
关键词
Soft tissue sarcoma; Retroperitoneal; Leiomyosarcoma; Liposarcoma; Overall survival; Progression-free survival; SOFT-TISSUE SARCOMA; CANCER-CENTERS-SARCOMA; FRENCH-FEDERATION; ADJUVANT CHEMOTHERAPY; PROGNOSTIC-FACTORS; ADULT PATIENTS; ANATOMIC SITE; SURVIVAL; HISTOLOGY; NOMOGRAMS;
D O I
10.1186/s12957-018-1505-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Retroperitoneal soft tissue sarcomas (STS) include a number of histologies but are rare, with approximately 3000 cases in the USA per year. Retroperitoneal STS have a high incidence of local and distant recurrence. The purpose of this study was to review the University of Maryland Medical Center's (UMMC) treatment experience of retroperitoneal STS, where the patient population served represents a diverse socioeconomic and ethnic catchment. Methods: IRB approval was obtained. We constructed a de-identified database of patients diagnosed with retroperitoneal liposarcomas (LPS) or leiomyosarcomas (LMS) treated at UMMC between 2000 and 2013. A total of 49 patients (Pts) with retroperitoneal STS met our eligibility criteria. Kaplan-Meier plots were used to graphically portray progression-free survival (PFS) and overall survival (OS). The log-rank test was used to compare time-to-event distributions. Results: The median OS for all patients (Pts) was 6.3 years, and the 2-year OS rate was 81%. The median PFS for all Pts was 1.8 years, and the 2-year PFS rate was 45%. There was no difference in OS and PFS among LMS and LPS patients; the median OS for LMS was 3.8 years vs. LPS 6.4 years (p = 0.33), and the median PFS for LMS was 1.2 years vs. LPS 2.5 years (p = 0.28). There was a significant difference between histology and race (p = 0.001). LPS were primarily Caucasian 86% vs. 14% black, whereas LMS were primarily black 52% vs. 33% Caucasian. OS was influenced by functional status, gender, American Joint Committee on Cancer (AJCC) stage, grade, histology, tumor size, and extent of resection. PFS was influenced by AJCC stage, grade, and extent of resection. Neither adjuvant chemotherapy (1 Pt) nor neoadjuvant/adjuvant radiation therapy (18 Pts) influenced OS or PFS. There was a non-significant difference that Pts who could undergo resection of local recurrence had improved 2-year OS, with 100% LMS and LPS compared to 2-year OS of 71% (LMS) and 78% (LPS) not undergoing resection of local recurrence. Conclusions: This study suggests a higher incidence of leiomyosarcoma in the African-American population. This study confirms the prognostic importance of grade, tumor size, AJCC stage, histology, and extent of resection in patient outcomes, at a large substantially diverse academic medical center. Future research into the biological features of liposarcoma and leiomyosarcoma Pts imparting these characteristics will be important to define.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Surgical resection for recurrent retroperitoneal leiomyosarcoma and liposarcoma
    Michael J Nathenson
    Constance M Barysauskas
    Robert A Nathenson
    William F Regine
    Nader Hanna
    Edward Sausville
    World Journal of Surgical Oncology, 16
  • [2] Multiply recurrent retroperitoneal liposarcoma
    Bagaria, Sanjay P.
    Gabriel, Emmanuel
    Mann, Gary N.
    JOURNAL OF SURGICAL ONCOLOGY, 2018, 117 (01) : 62 - 68
  • [3] En Bloc Resection of a Giant Retroperitoneal Liposarcoma: A Surgical Challenge
    Almas, Talal
    Ullah, Muneeb
    Ehtesham, Maryam
    Akbar, Absam
    Khan, Muhammad Kashif
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2020, 12 (06)
  • [4] Secondary surgical resection for patients with recurrent uterine leiomyosarcoma
    Cybulska, Paulina
    Sioulas, Vasileios
    Orfanelli, Theofano
    Zivanovic, Oliver
    Mueller, Jennifer J.
    Broach, Vance A.
    Roche, Kara C. Long
    Sonoda, Yukio
    Hensley, Martee L.
    O'Cearbhaill, Roisin E.
    Chi, Dennis S.
    Alektiar, Kaled M.
    Abu-Rustum, Nadeem R.
    Leitao, Mario M., Jr.
    GYNECOLOGIC ONCOLOGY, 2019, 154 (02) : 333 - 337
  • [5] Surgical Treatment of Retroperitoneal Liposarcoma
    Ikeguchi, Masahide
    Urushibara, Shoichi
    Shimoda, Ryugo
    Saito, Hiroaki
    Wakatsuki, Toshiro
    YONAGO ACTA MEDICA, 2014, 57 (04) : 129 - 132
  • [6] Comparison between retroperitoneal leiomyosarcoma and dedifferentiated liposarcoma
    Ishii, Takeaki
    Kohashi, Kenichi
    Ootsuka, Hiroshi
    Iura, Kunio
    Maekawa, Akira
    Yamada, Yuichi
    Bekki, Hirofumi
    Yoshimoto, Masato
    Yamamoto, Hidetaka
    Iwamoto, Yukihide
    Oda, Yoshinao
    PATHOLOGY RESEARCH AND PRACTICE, 2017, 213 (06) : 634 - 638
  • [7] Retroperitoneal Liposarcoma A Comprehensive Review
    Vijay, Adarsh
    Ram, Lakshmi
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2015, 38 (02): : 213 - 219
  • [8] Resection outcomes for primary and local recurrent retroperitoneal liposarcoma patients
    Yan, Yang
    Xia, Shaoyou
    Teng, Da
    Hu, Shidong
    Li, Songyan
    Wang, Yufeng
    Du, Xiaohui
    Li, Rong
    ANNALS OF TRANSLATIONAL MEDICINE, 2020, 8 (21)
  • [9] RECURRENT RETROPERITONEAL LIPOSARCOMA
    Tuzel, Emre
    Guler, Cem
    Tokyol, Cigdem
    Aktepe, Fatma
    Arikan, Yuksel
    TURKISH JOURNAL OF UROLOGY, 2007, 33 (01): : 128 - 130
  • [10] Recurrent retroperitoneal liposarcoma: A case report and literature review
    Mulita, Francesk
    Verras, Georgios-Ioannis
    Liolis, Elias
    Tchabashvili, Levan
    Kehagias, Dimitrios
    Kaplanis, Charalampos
    Perdikaris, Ioannis
    Kehagias, Ioannis
    CLINICAL CASE REPORTS, 2021, 9 (09):